GENPREX (GNPX) Competitors $0.28 -0.01 (-2.33%) Closing price 04:00 PM EasternExtended Trading$0.28 +0.00 (+1.12%) As of 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GNPX vs. INKT, PASG, SCYX, DYAI, ENLV, COEP, TPST, NRSN, CVKD, and CGTXShould you be buying GENPREX stock or one of its competitors? The main competitors of GENPREX include MiNK Therapeutics (INKT), Passage Bio (PASG), SCYNEXIS (SCYX), Dyadic International (DYAI), Enlivex Therapeutics (ENLV), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), and Cognition Therapeutics (CGTX). These companies are all part of the "pharmaceutical products" industry. GENPREX vs. Its Competitors MiNK Therapeutics Passage Bio SCYNEXIS Dyadic International Enlivex Therapeutics Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics MiNK Therapeutics (NASDAQ:INKT) and GENPREX (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has better valuation and earnings, INKT or GNPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.52-8.06GENPREXN/AN/A-$21.11MN/AN/A Do analysts recommend INKT or GNPX? MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 84.64%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe MiNK Therapeutics is more favorable than GENPREX.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33GENPREX 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals hold more shares of INKT or GNPX? 2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of GENPREX shares are owned by institutional investors. 22.5% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 8.5% of GENPREX shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is INKT or GNPX more profitable? MiNK Therapeutics' return on equity of 0.00% beat GENPREX's return on equity.Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -140.72% GENPREX N/A -664.65%-370.18% Does the media refer more to INKT or GNPX? In the previous week, MiNK Therapeutics had 16 more articles in the media than GENPREX. MarketBeat recorded 16 mentions for MiNK Therapeutics and 0 mentions for GENPREX. GENPREX's average media sentiment score of 1.87 beat MiNK Therapeutics' score of 0.12 indicating that GENPREX is being referred to more favorably in the news media. Company Overall Sentiment MiNK Therapeutics Neutral GENPREX Very Positive Which has more risk & volatility, INKT or GNPX? MiNK Therapeutics has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, GENPREX has a beta of -0.5, suggesting that its share price is 150% less volatile than the S&P 500. SummaryMiNK Therapeutics beats GENPREX on 9 of the 11 factors compared between the two stocks. Get GENPREX News Delivered to You Automatically Sign up to receive the latest news and ratings for GNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNPX vs. The Competition Export to ExcelMetricGENPREXMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.40M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / SalesN/A303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book1.857.678.125.65Net Income-$21.11M-$55.28M$3.25B$257.91M7 Day PerformanceN/A2.50%0.97%2.09%1 Month Performance-8.31%11.70%7.36%11.13%1 Year Performance-86.16%4.89%31.31%18.40% GENPREX Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNPXGENPREX1.3581 of 5 stars$0.28-2.3%N/A-85.8%$9.40MN/A0.0020INKTMiNK Therapeutics2.5494 of 5 stars$7.28+0.6%$37.50+415.5%+121.4%$28.82MN/A-2.8930Analyst DowngradePASGPassage Bio2.5741 of 5 stars$0.43-6.1%$7.50+1,632.1%-69.3%$28.66MN/A-0.42130Stock SplitSCYXSCYNEXIS0.9185 of 5 stars$0.71-3.2%N/A-65.9%$28.54M$3.75M-1.2660Positive NewsDYAIDyadic International3.0328 of 5 stars$0.92-2.6%$6.00+555.4%-31.5%$28.28M$3.49M-4.587Positive NewsGap DownENLVEnlivex Therapeutics2.7186 of 5 stars$1.21+2.5%$10.00+726.4%-13.7%$27.91MN/A-1.8370Positive NewsCOEPCoeptis Therapeutics0.412 of 5 stars$7.73+2.5%N/A+93.1%$26.49MN/A-1.332TPSTTempest Therapeutics2.3833 of 5 stars$7.08-0.7%$30.00+323.7%-75.6%$26.26MN/A-0.3920Positive NewsNRSNNeuroSense Therapeutics2.5015 of 5 stars$2.09+9.4%$14.00+569.9%+150.1%$26.10MN/A-3.8710CVKDCadrenal Therapeutics2.9665 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics2.9505 of 5 stars$0.58+42.9%$2.83+389.5%-64.6%$25.11MN/A-0.7820High Trading Volume Related Companies and Tools Related Companies INKT Competitors PASG Competitors SCYX Competitors DYAI Competitors ENLV Competitors COEP Competitors TPST Competitors NRSN Competitors CVKD Competitors CGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNPX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GENPREX Please log in to your account or sign up in order to add this asset to your watchlist. Share GENPREX With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GNPX Stock Alerts